1 |
Adams, J. E. 3rd., Bodor, G. S., Davila-Roman, V.G., Delmez, J. A., Apple, F. S., Ladenson, J. H., and Jaffe, A. S., Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation, 88, 101-106 (1993)
DOI
ScienceOn
|
2 |
Baker, C. S., Hall, R. J., Evans, T. J., Pomerance, A., Maclouf, J., Creminon, C., Yacoub, M. H., and Polak, J.M., Cyclooxygenase- 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler. Thromb. Vasc. Biol., 19, 646-655 (1999)
DOI
ScienceOn
|
3 |
Koenig, W., Inflammation and coronary heart disease: an overview. Caridol. Rev., 9, 31-35 (2001)
DOI
ScienceOn
|
4 |
Langendorff. Pfluners Arch. Ges. Physiol., 190, 280 (1985)
|
5 |
Mobert, J. and Becker, B. F., Cyclooxygenase inhibition aggravates ischaemia-reperfusion injury in the perfused guinea pig heart: involvement of isoprostanes. J. Am. Coll. Cardiol., 31, 1687-1694 (1998)
DOI
ScienceOn
|
6 |
Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M., and Geis, G. S., Gastrointestinal toxicity with celecoxib vs nonsterodial anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study. A randomized control trial. JAMA, 284, 1247- 1255 (2000)
DOI
ScienceOn
|
7 |
O'Banion M., Cyclooxygenase-2: Molecular biology, pharmacology and neurobiology. Critc. Rev. Neurobiol., 13, 45-82 (1999)
DOI
|
8 |
Saito, T., Rodger, I. W., Hu, F., Shennib, H., and Giaid, A., Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem. Biphys. Res. Commun., 273, 772-775 (2000)
DOI
ScienceOn
|
9 |
Schonbeck, U., Sukhova, G. K., Graber, P., Coulter, S., and Libby, P., Augmented expressoin of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol., 155, 1281- 1291 (1999)
DOI
ScienceOn
|
10 |
Chenevard, R., Hurlimann, D., Bechir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., Michel, B., Luscher, T. F., Noll, G., and Ruschitzka, F., Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation, 107, 405-409 (2003)
DOI
ScienceOn
|
11 |
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos- Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., and Schnitzer, T. J., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N. Engl. J. Med., 243, 1520-1528 (2000)
|
12 |
Rosalki, S. B., An improved procedure for serum creatine phosphokinase determination. J. Lab. Clin. Med., 69, 696- 705 (1967)
|
13 |
Saeed, S. A., Atiq, M., Virani, S., and Gilani, A. H., New vistas in the therapeutic uses of aspirin. Res. Commun. Pharmacol. Toxicol., 6, 277-296 (2001)
|
14 |
Duffy, S. J., Castle, S. F., Harper, R. W. et al., Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilatation, and flow-mediated dilation in human coronary circulation. Circulation, 100, 1951-1957 (1999)
DOI
ScienceOn
|
15 |
Heitzer, T., Just, H., and Munzel, T., Antioxidant vitamin C improves and endothelial dysfunction in chronic smokers. Circulation, 94, 6-9 (1996)
DOI
ScienceOn
|
16 |
Lecomte, M., Laneuville, O., Ji, C., DeWitt, D. L., and Smith, W. L., Acetylation of human prostaglandin endoperoxide synthase- 2 (cyclooxygenase-2) by aspirin. J. Biol. Chem., 269, 13207- 13215 (1994)
|
17 |
Bonow, R. O., Lipson, L. C., Shaheen, F. H., Capurro, N. L., Inser, J. M., Roberst, W.C., Goldstein, R. E., and Epstein, S.E., Lack of effect of aspirin on myocardial infarct size in dogs. Am. J. Cardiol., 47, 258-264 (1981)
DOI
ScienceOn
|
18 |
Cai, H. and Harrison, D. G., Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Cirs. Res., 87, 840-844 (2000)
DOI
ScienceOn
|
19 |
Mukerjee, D., Nissen, S. E., and Topol, E. J., Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286, 954-959 (2001)
DOI
ScienceOn
|
20 |
Saeed, S. A., Gilani, A. H., Sultan, B. H., Karim, R. M., and Shah, B. H., Myocardial ischemia and infarction in isoprenalinetreated rabbits: Role of cyclooxygenases. Bichem. Soc. Trans., 26, S342 (1998)
DOI
|
21 |
Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D. J., Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation, 102, 840- 845 (2000)
DOI
ScienceOn
|
22 |
Mukerjee, D., Selective Cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem. Pharmacol., 63, 817-21 (2002)
DOI
ScienceOn
|